Predictors of the therapeutic effect of Nab-paclitaxel plus gemcitabine therapy for patients with recurrent pancreatic cancer after pancreatectomy

Author:

Kawaida Hiromichi1,Hosomura Naohiro1,Amemiya Hidetake1,Saito Ryo1,Shoda Katsutoshi1,Furuya Shinji1,Akaike Hidenori1,Kawaguchi Yoshihiko1,Kono Hiroshi1,Fukasawa Yoshimitsu1,Kawakami Satoshi1,Shindo Hiroko1,Takahashi Ei1,Takano Shinichi1,Fukasawa Mitsuharu1,Simizu Tatsuya1,Itakura Jun1,Enomoto Nobuyuki1,Fujii Hideki1,Ichikawa Daisuke1

Affiliation:

1. University of Yamanashi

Abstract

Abstract Background/Aim Nab-paclitaxel plus gemcitabine (GnP) is one of the standard chemotherapeutic schemes of treatment of advanced pancreatic cancer (PC). The current study has the aim to outline the predictors of therapeutic effect of GnP in the cases with recurrent PC after pancreatectomy. Patients and Methods We retrospectively evaluated the clinicopathological characteristics of patients with recurrent PC after pancreatectomy who received GnP at our institution from January 2016 to February 2021. We examined various inflammatory markers [neutrophil lymphocyte ratio (NLR), lymphocyte monocyte ratio (LMR), platelet lymphocyte ratio (PLR), C-reactive protein albumin ratio (CAR)] and a nutritional marker [ prognostic nutritional index (PNI) ] in addition to common clinicopathological characteristics as possible predictors of the chemotherapeutic effects of GnP. Results Univariate analysis identified PLR, CAR, and histological differentiation as significant predictors of better chemotherapeutic effects. Meanwhile, multivariate analysis identified only histological differentiation as an independent predictor of better chemotherapeutic effects. Accordingly, patients with well-differentiated adenocarcinoma showed better overall survival after recurrence than those with other histological types. Conclusion Histological differentiation can be a useful predictor of the therapeutic effects of GnP in the clinical cases of recurrent PC after pancreatectomy.

Publisher

Research Square Platform LLC

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3